325 related articles for article (PubMed ID: 26100884)
41. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
43. Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.
Yi YW; Park JS; Kwak SJ; Seong YS
Anticancer Res; 2015 Jul; 35(7):3829-38. PubMed ID: 26124328
[TBL] [Abstract][Full Text] [Related]
44. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
[TBL] [Abstract][Full Text] [Related]
45. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
47. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
48. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
Sun CK; Zhang F; Xiang T; Chen Q; Pandita TK; Huang Y; Hu MC; Yang Q
Oncotarget; 2014 May; 5(10):3375-85. PubMed ID: 24831086
[TBL] [Abstract][Full Text] [Related]
49. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
50. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
51. Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Zhang H; Yu N; Chen Y; Yan K; Wang X
J Cell Biochem; 2019 Aug; 120(8):13037-13045. PubMed ID: 30873673
[TBL] [Abstract][Full Text] [Related]
52. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
54. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
55. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
56. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
[TBL] [Abstract][Full Text] [Related]
57. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
58. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
59. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
[TBL] [Abstract][Full Text] [Related]
60. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Jaspers JE; Sol W; Kersbergen A; Schlicker A; Guyader C; Xu G; Wessels L; Borst P; Jonkers J; Rottenberg S
Cancer Res; 2015 Feb; 75(4):732-41. PubMed ID: 25511378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
